Chembio Diagnostics surges following commercial launch of COVID-19/Flu A&B test Check out this evening's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Chembio Diagnostics (CEMI) up 44% after announcing the commercial launch of an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19/Flu A&B test, for use in decentralized and traditional testing settings
- Genius Sports (DMYD) up 25% after CNBC reported the National Football League has agreed to a multi-year partnership with the company
- Turtle Beach (HEAR) up 1% after its board of directors approved an extension and expansion of its share repurchase program up to $25M
- CTO Realty Growth (CTO) up 1% after filing $350M mixed securities shelf
- Future FinTech (FTFT) up 1% after signing an acquisition framework agreement to acquire Nanjing Ribensi which currently operates a bitcoin mining farm with a capacity to operate 30,000 bitcoin mining machines
DOWN AFTER EARNINGS -
- Franklin Covey (FC) down 4%
LOWER -
- Everspin Technologies (MRAM) down 1% after announcing that Daniel Berenbaum has notified the company of his decision to resign as CFO to pursue another opportunity overseas
- City Office REIT (CIO) down 1% after filing $500M mixed securities shelf
- Unique Fabricating (UFAB) down 8% after announcing that it will restate its previously issued quarterly financial statements for the quarters ended March 31, 2020, June 30, 2020, and September 30, 2020
- Sonoma Pharmaceuticals (SNOA) down 6% after entering into an agreement with EMC Pharma for the exclusive right to manage, market and distribute Sonoma's HOCl-based prescription dermatology and eye care products in the United States for an initial term of five years, subject to extension
Symbols:
CEMI DMYD HEAR CTO FTFT FC MRAM CIO UFAB SNOA Keywords: Fly Intel, Wall Street, Top Stories, Stocks